Shelley Boyd, MD
President & Chief Scientific Officer
Translatum Medicus inc
Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She was formerly Head of the Ocular Angiogenesis Research Program, global, with Novartis (Switzerland), overseeing translational aspects of the Ranibizumab program. She is Director of the High Risk Dry AMD Clinic, University of Toronto, and Founder of Translatum Medicus inc and Tracery Ophthalmics, both selected as members of JLABS@Toronto. She is on the Board of the Ontario Bioscience Innovation Organization (OBIO).